Novorex

Specialized company in the development of
new small molecule drugs targeting mostly oncology and neurology diseases
using FBDD and artificial intelligence with pharmaceutical experts.

History

2025

Apr. Selected for the Global Collaboration Program(Dassault Systemes)

Apr. Selected for the 2025 National New Drug Development Project

May. Signed the first platform service contract

2024

Apr. MOU with Almac Group

Apr. Designated as a military service company

Oct. Selected for the Advanced Bio Industry Promotion R&D Project

2023

Sep. Series A bridge Funding

Nov. Attended Bio-Europe business partnering meeting @Munich, Germany

Nov. Commendation from the Minister of Health and Welfare

2022

Mar. Established Novorex Central Research Center

Oct. Attended Bio-Europe business partnering meeting @Leipzig, Germany

Nov. MOU with Dong-A ST

2021

Feb. Established Novorex Jeongeup Research Center (Target Validation)

Jun. Established Novorex Pangyo Research Center (Medi-chem)

Jul. Series A Funding

2020

Feb. Established Novorex Inc.

Mar. Funding from TIPS program (Discovery of new drug candidates and targets using deep learning)

Apr. Funding from angel investment

May. Certified Venture Company

Jun. Established Novorex Research Institute at Seoul

Nov. Certified Corporate-affiliated research institute

TOP